Financial navigation
Behavioralproviding financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
NCT Number: NCT04931251
The financial burden, or financial toxicity (FT), of cancer is a consequential and growing problem, particularly for rural patients. It is important to improve our understanding of how financial navigation (FN) can reduce the material, psychological, and behavioral burden of costs associated with cancer care in both rural and non-rural community settings. The purpose of this study is to conduct a financial navigation program in 5 rural and 4 non-rural oncology practices in North Carolina and evaluate the effects of financial navigation on patient outcomes, including financial toxicity and health-related quality of life.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
NC Basnight Cancer Hospital, Chapel Hill, North Carolina, United States
This study is designed to evaluate the implementation and effectiveness of a financial navigation intervention within 5 rural and 4 non-rural oncology settings in North Carolina. Financial navigators from each of the 9 sites will recruit and enroll 255 patients total across all sites into a financial navigation program. The financial navigation intervention consists of screening patients using the COST measure for financial toxicity. If the patient scores 23 or lower, they are considered to have moderate to severe financial toxicity and will be enrolled in the study. Patients will then complete a series of baseline questionnaires to measure their health related quality of life and then they will meet with a financial navigator for a comprehensive intake process to determine potential financial assistance resources the patient may be eligible for and continued visits with the financial navigator until all financial assistance resources have been explored and patients have received benefits or referrals to financial assistance programs. At the end of the intervention, the patients will complete the COST measure again, and repeat baseline surveys to measure health-related quality of life and the patient's acceptability and responsiveness of the financial navigation intervention. Patient participation depends on the depth of patient need but ranges from 2 visits to 6 visits with the financial navigator over approximately 4 months but possibly longer depending on the complexity of the patient's financial need.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
Time frame: 4-6 months
To evaluate the change from baseline to follow-up in scores from the Comprehensive Score for Financial Toxicity (COST) measure after participation in the financial navigation program among 780 rural and non-rural NC cancer patients with high baseline financial distress.
Time frame: 4-6 months
To evaluate the change from baseline to follow-up in scores from HRQoL, care-altering behaviors and patient perspectives on the intervention itself
UNC Lineberger Comprehensive Cancer Center
Other
Addressing Cancer-Related Financial Toxicity in Rural North Carolina Oncology Care Settings
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03037385
Adenocarcinoma, Adenocarcinoma, Papillary
Phoenix, Arizona, United States
View Trial DetailsNCT04008082
Adenocarcinoma, Carcinoma
Osaka, Japan
View Trial DetailsNCT00420381
Adnexal Diseases, Carcinoma
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT00879684
Advanced Solid Tumors, Cancer
Scottsdale, Arizona, United States
View Trial Details